Processa Pharmaceuticals (PCSA) Income towards Parent Company (2012 - 2026)

Processa Pharmaceuticals (PCSA) has 15 years of Income towards Parent Company data on file, last reported at -$3.4 million in Q1 2026.

• Quarterly Income towards Parent Company fell 19.15% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.5 million (down 22.9% YoY) and the FY2025 annual result came in at $2.5 million, up 121.92% from the prior year.
• Income towards Parent Company improved to -$3.4 million in Q1 2026, from -$3.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$2.3 million in Q3 2023 to a low of -$20.0 million in Q4 2023.
• A 5-year average of -$5.0 million and a median of -$3.5 million in 2024 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 308.7% — and 2024, when it surged 87.54%.
• Tracing PCSA's Income towards Parent Company over 5 years: stood at -$13.0 million in 2022, then sank by 54.04% to -$20.0 million in 2023, then surged by 87.54% to -$2.5 million in 2024, then tumbled by 48.28% to -$3.7 million in 2025, then grew by 8.77% to -$3.4 million in 2026.
• The last three Income towards Parent Company figures came in at -$3.4 million (Q1 2026), -$3.7 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.